Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Breakthrough Status May Not Be So Groundbreaking, Recent Reviews Indicate

Executive Summary

A look at some of FDA’s novel drug approvals analyzed in Pharmaceutical Approvals Monthly’s 2012 series of drug review profiles suggests that the agency has already ushered through several approvals that could be models for the new “breakthrough” designation created by the FDA Safety and Innovation Act.

Advertisement

Related Content

Breaking Down the First “Breakthrough”
Enriched Trials Not Just About Marker-Positive Patients, FDA Says
“Breakthrough Therapy” Development Speed May Be Tempered By Manufacturing Hurdles
Industry Wants A Breakthrough Therapy, Even Without All The Standards
New Paradigm Would Open More Avenues To Obesity Drug Approval
Xarelto Tested FDA’s Comparative Efficacy Powers, But Conservative View Prevailed
Xalkori And The Art Of Modern Drug Development
Xarelto Review Puts FDA’s Comparative Effectiveness Stance To The Test
Oncology Has Different Risk Management Standards, FDA’s Pazdur Acknowledges
Effient Review Delayed More By Management Issues Than Clinical Disputes

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS055079

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel